BioSpace News Archive

Vivos Therapeutics, Inc. today announced that it has been granted 510(k) clearance from the U.S. Food and Drug Administration (FDA) for treating severe obstructive sleep apnea (OSA) in adults using the Vivos’ removable CARE (Complete Airway Repositioning and/or Expansion) oral appliances.

Apollomics Inc. today announced that Guo-Liang Yu, Ph.D., Co-Founder and Chief Executive Officer of Apollomics and Sanjeev Redkar, Ph.D., Co-Founder and President, will participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference on Wednesday, December 6, 2023 at 11:30 a.m. ET.

INmune Bio, Inc. is presenting data on the use of INB03, a dominant-negative TNF inhibitor of soluble TNF (sTNF) in the treatment of high-risk MUC4 expressing HER2.

MIRA Pharmaceuticals, Inc. today announced results from recent studies that indicate Ketamir-2’s oral bioavailability is predicted to be approximately 80%.

Halia Therapeutics today announced positive results following the successful completion of a Phase 1 clinical trial for its leading candidate, HT-6184.

Wiley will release its second quarter 2024 results prior to market open on Wednesday, December 6, 2023.

Processa Pharmaceuticals, Inc. announces that CEO George Ng has issued a letter to shareholders.

Arrivo BioVentures today announced the closing of an oversubscribed Series B preferred financing round, totaling $100M.

Panbela Therapeutics, Inc. announces that the independent Data Safety Monitoring Board (DSMB) of the Phase 3 ASPIRE clinical trial for patients with untreated metastatic pancreatic ductal adenocarcinoma has completed its pre-specified review of safety data for treated patients.

Today, PrecisePK announces its significant strides in transforming healthcare in South America through integration into key healthcare and educational institutions.